[
  {
    "id": "E01",
    "title": "The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed",
    "org": "Novo Nordisk",
    "date": "2024-12-18",
    "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915081",
    "loc": "Company announcement 98/2024, opening paragraphs",
    "scope": "Transaction completed 18 Dec 2024; three manufacturing sites",
    "en": "Confirms completion and the distinction between the two acquirers.",
    "limen": "Does not establish site-level GLP-1 output or utilisation.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "E02",
    "title": "Catalent Clarifies Novo Nordisk Ownership of Former Bloomington, Indiana Site",
    "org": "Catalent",
    "date": "2026-06-22",
    "url": "https://catalent.com/news/catalent-clarifies-novo-nordisk-ownership-of-former-bloomington-indiana-site",
    "loc": "Main statement, ownership paragraphs",
    "scope": "Bloomington, Indiana; ownership since Dec 2024",
    "en": "Confirms ownership and operation by Novo Nordisk.",
    "limen": "Legacy filing names do not establish current ownership.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "E03",
    "title": "Resolution of Shortages of Semaglutide Injection Products; FDA policies for compounders",
    "org": "US FDA",
    "date": "2025-02-21; policy page subsequently updated",
    "url": "https://www.fda.gov/media/185526/download\nhttps://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize",
    "loc": "Order pp.1–3; policy page entries dated 21 Feb 2025 and later",
    "scope": "US national semaglutide-injection shortage determination",
    "en": "Supports national resolution, possible local disruptions and changed shortage-related conditions.",
    "limen": "Historical decision, not every GLP-1 product or worldwide availability; not legal advice.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "E04",
    "title": "Obesity and overweight",
    "org": "WHO",
    "date": "2026-10-07",
    "url": "https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight",
    "loc": "Key facts; Prevalence of overweight and obesity",
    "scope": "Global adults aged 18+; 2024 estimates",
    "en": "An estimated 940 million adults had obesity in 2024, about 16% of adults.",
    "limen": "Prevalence is not a paid pharmaceutical market or prescription forecast.",
    "kind": "Official statistical synthesis",
    "access": "2026-10-21"
  },
  {
    "id": "E05",
    "title": "WHO issues global guideline on the use of GLP-1 medicines in treating obesity",
    "org": "WHO",
    "date": "2025-12-01",
    "url": "https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity",
    "loc": "Landmark policy change; Implementation considerations",
    "scope": "Global guideline context; adult obesity",
    "en": "Cost, long-term evidence, system readiness and equity inform conditional recommendations.",
    "limen": "Guidance is not country-level reimbursement or product approval; not personal prescribing advice.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "E06",
    "title": "Ozempic: Summary of Product Characteristics",
    "org": "European Medicines Agency",
    "date": "Live product information; read 2026-10-21",
    "url": "https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf",
    "loc": "Annex I, section 2, printed p.3",
    "scope": "Assessed originator semaglutide product",
    "en": "Identifies recombinant Saccharomyces cerevisiae manufacture.",
    "limen": "Not all suppliers or proof of universally lowest process cost.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "E07",
    "title": "Wegovy injection and tablets: Prescribing information",
    "org": "US FDA",
    "date": "Revised 12/2025",
    "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
    "loc": "Sections 2.1–2.3, printed pp.4–5; section 11",
    "scope": "US approval-era label; formulations and strengths",
    "en": "Supports 25 mg daily tablet maintenance and administration conditions, used to discuss input demand.",
    "limen": "Historical label, not comprehensive current prescribing guidance; dose is not comparative efficacy.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "E08",
    "title": "FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide",
    "org": "US FDA",
    "date": "2026-03-19",
    "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide\nhttps://www.sec.gov/Archives/edgar/data/353278/000117184326001813/f6k_031926.htm",
    "loc": "Opening and indication paragraphs; SEC-filed 19 March 2026 announcement, opening paragraph for once-weekly schedule",
    "scope": "US approval; Wegovy HD 7.2 mg injection",
    "en": "Confirms higher-dose injectable approval beyond the 2025 label.",
    "limen": "Not prescribing advice or an indirect efficacy ranking.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "E09",
    "title": "FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes",
    "org": "US FDA",
    "date": "2024-12-23",
    "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes",
    "loc": "Opening paragraph and approval recipient",
    "scope": "US; generic referencing Victoza",
    "en": "Confirms first generic approval referencing Victoza.",
    "limen": "Does not imply identical generic pathways or immediate access for every GLP-1.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "E10",
    "title": "FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss",
    "org": "US FDA",
    "date": "Live page; accessed 2026-10-21",
    "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
    "loc": "Unapproved versions; Retatrutide and cagrilintide; Actions at the border; Shipping; Dosing concerns",
    "scope": "US regulatory and quality warnings",
    "en": "Supports distinctions from approved products, investigational ingredients, quality and import risks.",
    "limen": "Warnings are not incidence estimates; import alert is not a blanket country ban.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "M01",
    "title": "Financial report for 1 January–31 December 2025; Annual Report 2025",
    "org": "Novo Nordisk",
    "date": "2026-02-03",
    "url": "https://www.sec.gov/Archives/edgar/data/353278/000035327826000006/caq42025.htm\nhttps://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.html",
    "loc": "Financial report p.7, GLP-1 diabetes table and footnotes; annual report therapeutic sales",
    "scope": "Global IQVIA value share, MAT November 2025; separate FY 2025 company sales, DKK",
    "en": "Share 45.8%, prior 55.1%; diabetes GLP-1 sales DKK 152,202 m, obesity DKK 82,347 m.",
    "limen": "Issuer-reported IQVIA; international tirzepatide classified as diabetes, incomplete coverage; share differs from net-sales basis.",
    "kind": "Primary issuer record containing third-party estimates",
    "access": "2026-10-21"
  },
  {
    "id": "M02",
    "title": "Lilly reports fourth-quarter 2025 financial results and provides 2026 financial guidance",
    "org": "Eli Lilly",
    "date": "2026-02-04",
    "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-reports-fourth-quarter-2025-financial-results-and-provides",
    "loc": "Selected Revenue Highlights",
    "scope": "Worldwide FY 2025 brand revenue, USD millions",
    "en": "Mounjaro US$22,965 m and Zepbound US$13,542 m; sum US$36,507 m.",
    "limen": "Brands do not map universally to one indication; not all Lilly GLP-1 revenue.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "M03",
    "title": "Wegovy tablets original approval package",
    "org": "US FDA",
    "date": "2025-12-22 approval",
    "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/218316Orig1s000Approv.pdf",
    "loc": "Approval letter, package pp.1 and 4",
    "scope": "US; adult indications specified in letter",
    "en": "Confirms approved oral semaglutide rather than pipeline-only technology.",
    "limen": "US approval is not simultaneous worldwide launch.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "M04",
    "title": "Foundayo approval letter and non-peptide product description",
    "org": "US FDA; Eli Lilly",
    "date": "2026-04-01",
    "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220934Orig1s000ltr.pdf\nhttps://lilly.gcs-web.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill",
    "loc": "FDA letter p.1 for approval and p.12 electronic signature for date; Lilly About Foundayo",
    "scope": "US adult weight-management approval; molecular modality",
    "en": "Confirms orforglipron approval and non-peptide small-molecule modality.",
    "limen": "No inference of other authorisations or universal suitability; not peptide API demand.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "M05",
    "title": "Financial report for 1 January–30 June 2026",
    "org": "Novo Nordisk",
    "date": "2026-08-04",
    "url": "https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm",
    "loc": "Pages 3–4,8–10,13; adjusted results and 340 B reversal",
    "scope": "H1 2026; DKK millions; interim unaudited/unreviewed",
    "en": "340 B reversal DKK 26,760 m; reported sales 175,311 m versus adjusted 148,551 m.",
    "limen": "Adjusted metrics are non-IFRS measures; revenue changes are not volume changes.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "M06",
    "title": "Lilly reports second-quarter 2026 financial results",
    "org": "Eli Lilly",
    "date": "2026-08-05",
    "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full",
    "loc": "Selected Revenue Highlights, six-month column",
    "scope": "Worldwide H1 2026; USD millions",
    "en": "Mounjaro US$18,605 m, Zepbound US$9,088 m, Foundayo US$98 m.",
    "limen": "Launch sales are not long-term share forecasts; stated sum excludes Trulicity.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "M07",
    "title": "Novo’s CagriSema was associated with 25% weight loss on average for women… [title abbreviated; REDEFINE 1 post hoc announcement]",
    "org": "Novo Nordisk",
    "date": "2026-10-20",
    "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=918569",
    "loc": "Opening bullets and investigational description",
    "scope": "Pipeline status at report cutoff",
    "en": "Still describes CagriSema as investigational.",
    "limen": "Cited only for investigational status, not efficacy estimates. Results and expected decisions are not approval.",
    "kind": "Primary record",
    "access": "2026-10-21"
  },
  {
    "id": "C01",
    "title": "HATU, Novabiochem, product 851013",
    "org": "Merck KGaA / Novabiochem",
    "date": "Undated product page; accessed 2026-10-21",
    "url": "https://www.merckmillipore.com/LT/en/product/mm/851013",
    "loc": "Properties; Description; Application; Related Categories",
    "scope": "Company-specific activity; periods as dated",
    "en": "Confirms Novabiochem coupling reagents and related peptide-synthesis products.",
    "limen": "Catalogue products establish capability, not customers, sales or share.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C02",
    "title": "Investor relations activity record 2023-006",
    "org": "Sunresin / 蓝晓科技",
    "date": "2023-11-16 (document date; URL uploaded January 2024)",
    "url": "https://www.sunresin.com/storage/posts/January2024/mF73Dc68wR2JrzNOkJog.PDF",
    "loc": "PDF p.3, question 3; p.2, question 1",
    "scope": "Company-specific activity; periods as dated",
    "en": "Discloses peptide solid-phase synthesis resins and chromatography equipment.",
    "limen": "Historical 2023 participation, not 2026 revenue or share; no named originator customer.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C03",
    "title": "The era of large-scale peptide & oligo purification with MCSGP has begun",
    "org": "Bachem / YMC-Chromacon",
    "date": "2024-01-10",
    "url": "https://www.bachem.com/knowledge-center/the-era-of-large-scale-peptide-oligo-purification-with-mcsgp-has-begun/",
    "loc": "Moving from batch mode to continuous production; How does continuous chromatography or MCSGP work?",
    "scope": "Company-specific activity; periods as dated",
    "en": "Continuous chromatography recycles side fractions, illustrating purification and solvent-handling bottlenecks.",
    "limen": "One molecule is not a sector-wide benchmark; the article does not adopt its performance percentages.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C04",
    "title": "Bachem confirms growth and expects a strong second half 2026",
    "org": "Bachem",
    "date": "2026-07-30",
    "url": "https://www.bachem.com/articles/news/ad-hoc/bachem-confirms-growth-and-expects-a-strong-second-half-2026/",
    "loc": "Group results; Sales by product category; Substantial capacity expansion",
    "scope": "Company-specific activity; periods as dated",
    "en": "Building K commercial GMP production and ramp-up costs; H1 EBITDA margin 25.4%, versus 29.1% a year earlier.",
    "limen": "Group includes oligonucleotides; these are not GLP-1-only financial results.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C05",
    "title": "Half-year Report 2026: Business review",
    "org": "PolyPeptide",
    "date": "2026-08-13 results release; report covers six months ended 2026-06-30",
    "url": "https://report.polypeptide.com/hyr/26/business-review",
    "loc": "Revenue and customer projects; Profitability; Operational progress; Mid-term outlook",
    "scope": "Company-specific activity; periods as dated",
    "en": "Belgian plant operated at target utilisation; additional assets at other sites remained in commissioning or ramp-up.",
    "limen": "Metabolic therapeutics is not identical to GLP-1; target utilisation percentage is undisclosed.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C06",
    "title": "2026 interim report",
    "org": "WuXi AppTec / WuXi TIDES / 药明康德",
    "date": "2026-08-04 filing; period ended 2026-06-30",
    "url": "https://static.cninfo.com.cn/finalpage/2026-08-04/1225455027.PDF",
    "loc": "PDF pp.11–12, management discussion, WuXi Chemistry / TIDES",
    "scope": "Company-specific activity; periods as dated",
    "en": "TIDES includes oligonucleotides and peptides; H1 revenue RMB 7.26 billion.",
    "limen": "Not GLP-1 revenue or proof of a named brand supply contract.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C09",
    "title": "2026 interim report",
    "org": "Asymchem / 凯莱英",
    "date": "2026-08-25 filing; period ended 2026-06-30",
    "url": "https://static.cninfo.com.cn/finalpage/2026-08-25/1225496302.PDF",
    "loc": "PDF pp.10–11, chemical macromolecule CDMO and formulation CDMO",
    "scope": "Company-specific activity; periods as dated",
    "en": "Chemical macromolecule platform covers peptides, oligonucleotides and toxin-linkers; project stages are disclosed.",
    "limen": "Planned reactor volume is not realised output; project counts are not order value.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C10",
    "title": "Hybio Wuhan Partners with GenTech to Forge New Paths in Peptide Industry Waste Liquid Resource Recovery",
    "org": "Hybio / 翰宇药业",
    "date": "2026-04-25",
    "url": "https://www.hybio.com/news/hybio-wuhan-partners-with-gentech-to-forge-new-paths-in-peptide-industry-waste-liquid-resource-recovery/",
    "loc": "Main release paragraphs 1–6",
    "scope": "Company-specific activity; periods as dated",
    "en": "Wuhan site describes a peptide-manufacturing waste-recovery project.",
    "limen": "Company project, not verified realised savings or an industry average.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C11",
    "title": "Commercial Supply and Peptide CDMO services",
    "org": "Sinopep-Allsino / 江苏诺泰澳赛诺生物制药股份有限公司 (688076)",
    "date": "Undated live corporate page; accessed 2026-10-21",
    "url": "https://www.sinopep.com/",
    "loc": "Our Services; Commercial Supply",
    "scope": "Company-specific activity; periods as dated",
    "en": "Sinopep-Allsino offers peptide API and formulation services.",
    "limen": "Company-stated capability, not actual GLP-1 output; do not confuse with Chengdu Shengnuo.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C12",
    "title": "CordenPharma Expands Peptide Platform with >€500 m Greenfield Facility Construction in the Basel Region of Switzerland",
    "org": "CordenPharma",
    "date": "2025-03-05",
    "url": "https://cordenpharma.com/articles/press-release-cordenpharma-expands-peptide-platform-with-more-than-500-million-euro-greenfield-facility-construction-near-basel-switzerland/",
    "loc": "Investment overview; Muttenz and Colorado capacity plans",
    "scope": "Company-specific activity; periods as dated",
    "en": "Announces European and US peptide-platform expansion plans.",
    "limen": "Planned commercial starts such as 2028 are not operating 2026 supply.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C07",
    "title": "End-to-end offering for Molly autoinjectors at Thermo Fisher's Ridgefield, New Jersey site",
    "org": "SHL Medical / Thermo Fisher Scientific",
    "date": "2026-03-19",
    "url": "https://www.shl-medical.com/news-insights/news/end-to-end-offering-molly-autoinjectors-thermo-fisher-ridgefield-new-jersey-site",
    "loc": "Press release main text",
    "scope": "Company-specific activity; periods as dated",
    "en": "SHL and Thermo Fisher collaborate on filling, autoinjector assembly and packaging.",
    "limen": "Not a disclosed GLP-1 brand contract or delivered output.",
    "kind": "Primary company disclosure",
    "access": "2026-10-21"
  },
  {
    "id": "C08",
    "title": "Financial report for 1 January–31 March 2026",
    "org": "Novo Nordisk",
    "date": "2026-05-06",
    "url": "https://www.sec.gov/Archives/edgar/data/353278/000035327826000018/caq12026.htm",
    "loc": "Legal matters, p.20",
    "scope": "China exclusivity litigation; India formulation litigation",
    "en": "Discloses Chinese exclusivity and other patent disputes; expiry is not guaranteed freedom to launch.",
    "limen": "Litigation allegations are not final court findings; verify rights, jurisdiction and date.",
    "kind": "Primary record",
    "access": "2026-10-21"
  }
]